Notably, tumor-induced osteoclastogenesis targeting OPCs was resistant to denosumab, infliximab, and osteoprotegerin (OPG) in contrast to positive controls, in which OPCs were also treated with RANKL or TNF-α. Here, TNFSF11 is linked to neoplasm.